Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
221 stopped studies mapped to Malignant Skin Neoplasm and descendants · 91% state a reason
Over the 221 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | N/A | withdrawn | Oct 15, 2019 | Rush University Medical Center | lack of resources | Other (stated, no rule matched) |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | Phase 2 | withdrawn | Aug 2, 2021 | Pega-One S.A.S. | Business decision | Sponsor / business decision |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | Phase 1 | terminated | Dec 14, 2021 | Codiak BioSciences | PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety… | Safety / toxicity |
| NCT01744171 | Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | Phase 1 | terminated | Dec 6, 2012 | Roswell Park Cancer Institute | Study was Suspended since 2018; PI decided to terminate. | Other (stated, no rule matched) |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With…(SOLAR) | Phase 2 | terminated | Oct 19, 2018 | miRagen Therapeutics, Inc. | The study was terminated early for business reasons, and not due to concerns regarding safety or… | Safety / toxicity |
| NCT01940809 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients… | Phase 1 | terminated | Sep 12, 2013 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02288897 | PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced… | Phase 3 | terminated | Nov 11, 2014 | Provectus Biopharmaceuticals, Inc. | Inadequate rate of enrollment | Enrollment / accrual |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous… | Phase 4 | terminated | Dec 23, 2014 | Polish Lymphoma Research Group | Slow recruitment | Enrollment / accrual |
| NCT03497455 | Utility of Digital Dermoscopy in the Skin Cancer Clinic | — | terminated | Apr 13, 2018 | Barco NV | COVID pandemic / Change in strategic direction | COVID-19 / pandemic |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous… | Phase 2 | terminated | May 22, 2007 | Cyclacel Pharmaceuticals, Inc. | slow accrual and financial resource limitation | Enrollment / accrual |
| NCT02355574 | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile…(INTEGRATE) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study endpoints completed with lower than anticipated enrollment. Last patient enrolled completed… | Enrollment / accrual |
| NCT02355587 | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous…(EXPAND) | — | terminated | Feb 4, 2015 | Castle Biosciences Incorporated | Study goals were met with smaller that expected study cohort. Last patient completed the study June… | Other (stated, no rule matched) |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell… | Phase 2 | terminated | Jun 25, 2007 | Novartis Pharmaceuticals | Recruitment was stopped on 15 June 2009 (early termination date) due to low prevalence of study… | Enrollment / accrual |
| NCT04681456 | Skin Cancer Oncology Radiation Evidence Registry(SCORER) | — | terminated | Dec 23, 2020 | GenesisCare USA | The study was stopped in order to reconfigure it as a PhaseII/III study | Other (stated, no rule matched) |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | N/A | withdrawn | Nov 26, 2014 | Rochester General Hospital | No participants were enrolled in the study. | Enrollment / accrual |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | Phase 2 | terminated | Jan 19, 2015 | Rochester General Hospital | Low enrollment | Enrollment / accrual |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated…(Pelican) | Phase 1 | withdrawn | Dec 12, 2018 | Turnstone Biologics, Corp. | insufficient suitable drug supply | Drug supply |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03425461 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating… | Phase 1 | terminated | Feb 7, 2018 | Jonsson Comprehensive Cancer Center | funding | Funding |
| NCT02867722 | Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast…(DaylightPDT) | N/A | withdrawn | Aug 16, 2016 | Brigham and Women's Hospital | The PI decided to not proceed with the trial due to lack of funding. | Funding |
| NCT03837457 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who…(PRISM) | Phase 2 | terminated | Feb 12, 2019 | miRagen Therapeutics, Inc. | Study no longer needed because eligible subjects may receive treatment with cobomarsen in a… | Other (stated, no rule matched) |
| NCT02699723 | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | Early Phase 1 | withdrawn | Mar 4, 2016 | Jean Yuh Tang | Logistics | Other (stated, no rule matched) |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary… | Phase 1 | withdrawn | Aug 6, 2018 | University of Texas Southwestern Medical Center | Unable to enroll patients that met enrollment criteria. | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous… | Phase 1 | terminated | Nov 18, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT04117373 | Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database | — | withdrawn | Oct 7, 2019 | University of Pennsylvania | The researchers were unable to answer the study question by utilizing the insurance claims database. | Other (stated, no rule matched) |
| NCT03603587 | Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.(BACCHUS) | N/A | terminated | Jul 27, 2018 | Centre Hospitalier Universitaire de Saint Etienne | Organisation issues | Other (stated, no rule matched) |
| NCT03524248 | Development of Real-time Image-guided Radiotherapy | N/A | terminated | May 14, 2018 | Fox Chase Cancer Center | Camera for study is being repaired | Other (stated, no rule matched) |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating… | Phase 2 | terminated | Oct 28, 2013 | University of Washington | Change in standard of care | Other (stated, no rule matched) |
| NCT03548610 | Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb… | N/A | withdrawn | Jun 7, 2018 | Brigham and Women's Hospital | None of the screened subjects were interested / eligible for enrollment. | Enrollment / accrual |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS… | Phase 2 | terminated | Oct 27, 2015 | University of California, San Francisco | Funding | Funding |
| NCT01445340 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | Phase 1 | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01369875 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | Phase 2 | terminated | Jun 9, 2011 | National Cancer Institute (NCI) | Premature closure. Protocol did not meet its primary objective. | Other (stated, no rule matched) |
| NCT01385943 | VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine(EUNET) | — | withdrawn | Jun 30, 2011 | Lucid, Inc. | Study not launched due to logistical issues that could not be resolved. | Other (stated, no rule matched) |
| NCT03757663 | UV Dosimetry Feedback in NMSC Patients | N/A | withdrawn | Nov 29, 2018 | University of Colorado, Denver | Study closed | Other (stated, no rule matched) |
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell… | Phase 1 | terminated | Nov 30, 2012 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01988831 | Efficacy of Propranolol Treatment to Prevent Melanoma Progression | Phase 2 | suspended | Nov 20, 2013 | University Hospital, Geneva | We must delay the study for some financial reasons | Funding |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT01060319 | A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies | — | withdrawn | Feb 2, 2010 | Stanford University | Business Decision | Sponsor / business decision |
| NCT02303041 | Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic… | Phase 2 | terminated | Nov 27, 2014 | Anne Chang | Business Decision | Sponsor / business decision |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Phase 1 | terminated | Feb 12, 2014 | NYU Langone Health | Low Accrual | Enrollment / accrual |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With… | Phase 1 | terminated | Sep 22, 2015 | MedImmune LLC | Company strategy | Sponsor / business decision |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | Phase 1 | terminated | Dec 30, 2014 | Case Comprehensive Cancer Center | PI Left | Investigator |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | Phase 2 | terminated | Jan 9, 2013 | University of Florida | Poor accrual | Enrollment / accrual |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | Phase 2 | terminated | Aug 13, 2009 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 23, 2022source: clinicaltrials